CRISPR Therapeutics AG remains a strong long-term buy due to the commercial success of its gene therapy Casgevy, which saw a 78% sequential sales increase in Q2, underscoring its blockbuster potential despite initial market skepticism. While new AI-driven gene editing technologies from companies like Anthropic introduce competitive and funding uncertainties, these innovations are not expected to impact clinical outcomes soon. The company's robust pipeline and effective management execution support continued optimism, though investors should watch for emerging AI biotech challenges to traditional gene editing investments.
Despite emerging AI-driven gene editing technologies creating some uncertainty, CRISPR Therapeutics AG remains a favored stock among Pluang investors, with 100% of order activity on the buy side as of September 25, 2026, 02:11 WIB. The stock price stands at USD 56.09, showing a modest 0.59% increase on the day, while its market cap is $5.39 billion. Investors typically hold CRSP for about 77 days on the platform, reflecting steady confidence in its long-term prospects.
